GlobalData on MSN17h
TC BioPharm completes dosing in Cohort A of Phase IIb trial for AML
The trial was designed to evaluate the therapy’s efficacy and safety in treating AML, as well as myelodysplastic syndromes.
Study sets benchmark for treatment of advanced cervical cancer
A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...
FDA Grants Fast-Track Designation To Cannabis Withdrawal Syndrome Drug
U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...
The American Journal of Managed Care14h
TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Scientific Research Publishing20h
Enhancing Predictive Analytics for Healthcare: Addressing Limitations and Proposing Advanced Solutions ()
The paper reviews some of the major issues that occur in the application of big data analytics and predictive modeling in ...
HCD Magazine11h
2025 Healthcare Design Predictions: Travis Tyson, Cleveland Clinic
Cleveland Clinic’s Travis Tyson discusses the potential of AI and the opportunity to maximize existing building footprints to ...
UroToday10h
ASCO GU 2025: Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with NMIBC Unresponsive to BCG
Exploratory outcome measures include health-related quality of life, overall survival, and biomarker assessments. A broad cross-section of geographically and socioeconomically diverse clinical sites ...